Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Drug

Novartis’s Iptacopan on Track for Priority Review Status in China for PNH Treatment

Fineline Cube Jun 5, 2023

China’s Center for Drug Evaluation (CDE) website has indicated that Swiss pharmaceutical giant Novartis’ (NYSE:...

Company Deals

CSPC Pharmaceutical Group Partners with China Unicom for Digital Transformation

Fineline Cube Jun 5, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a strategic partnership with Chinese mobile...

Company Drug

Novo Nordisk’s Semaglutide for Weight Loss Accepted for Review by China’s NMPA

Fineline Cube Jun 5, 2023

Denmark-headquartered Novo Nordisk (NYSE: NVO) has announced that its market filing for the glucagon-like peptide-1...

Company Drug

Qilu Pharmaceutical Gains Temporary FDA Approval to Import Cisplatin Amid US Shortage

Fineline Cube Jun 5, 2023

Qilu Pharmaceutical, a China-based firm, has benefited from the effects of drug shortages in the...

Policy / Regulatory

CDE Releases 70th Batch of Generic Reference Preparations for Public Feedback

Fineline Cube Jun 5, 2023

The Center for Drug Evaluation (CDE) has released the 70th batch of chemical generic reference...

Company Drug

CStone Pharmaceuticals and Blueprint Medicines’ Ayvakit Wins FDA Approval for ISM Treatment

Fineline Cube Jun 5, 2023

Partners CStone Pharmaceuticals (HKG: 2616) and Blueprint Medicines have announced that the US FDA has...

Company Deals

Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01

Fineline Cube Jun 5, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm...

Company Drug

Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G

Fineline Cube Jun 2, 2023

Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical...

Company Drug

CANbridge Pharmaceuticals’ Maralixibat Approved by NMPA for Alagille Syndrome

Fineline Cube Jun 2, 2023

China-based rare disease specialist CANbridge Pharmaceuticals Inc., (HKG: 1228) has announced receiving market approval from...

Company Deals Drug

Innovent Biologics Partners with Merck KGaA to Test KRAS Inhibitor Combo in NSCLC

Fineline Cube Jun 2, 2023

China-based Innovent Biologics (HKG: 1801) has announced a clinical study and supply agreement with German...

Company Deals

Shenzhen Abrobo Medical Robot Secures RMB 100 Million in Series A Financing for Robotic Development

Fineline Cube Jun 2, 2023

Shenzhen Abrobo Medical Robot Co, Ltd has reportedly raised RMB 100 million via a Series...

Company Drug

Akeso Biopharma’s Ebronucimab NDA Accepted for Review by China’s NMPA

Fineline Cube Jun 2, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Eikon Therapeutics Inks Licensing Deals and Raises Funds for Drug Pipeline Expansion

Fineline Cube Jun 2, 2023

US biotech company Eikon Therapeutics has announced three in-licensing deals this week, one of which...

Company Deals

Sino Biopharmaceutical’s Subsidiary invoX Completes Additional Investment in pHion Therapeutics

Fineline Cube Jun 2, 2023

The UK-based invoX Pharma Ltd, a wholly-owned subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177),...

Company Deals

Ucello Therapeutics Secures RMB 150 Million in Series A+ Financing for CAR-T Cell Therapy

Fineline Cube Jun 2, 2023

Ucello Therapeutics, a developer of allogeneic universal chimeric antigen receptor (CAR)-T cell therapies based in...

Company Deals

Eversana Forms Strategic Alliance with China Resource Pharmaceutical for Healthcare Expansion

Fineline Cube Jun 2, 2023

US-based commercial services provider Eversana has announced a strategic alliance with China Resource Pharmaceutical Commercial...

Company Deals

Adcendo ApS Expands Partnership with Duality Biologics for Two Additional ADCs

Fineline Cube Jun 2, 2023

Denmark-based Adcendo ApS has announced the expansion and exercise of options to two additional antibody...

Policy / Regulatory

State Council Mandates Enhanced Oversight of Medical Insurance Funds Utilization

Fineline Cube Jun 1, 2023

The State Council has issued the “Implementation Opinions on Strengthening the Normalization Supervision of the...

Policy / Regulatory

NMPA Issues Procedures for Enhancing Children’s Medication Information in Drug Inserts

Fineline Cube Jun 1, 2023

The National Medical Products Administration (NMPA) has released the “Procedures for Adding Children’s Medication Information...

Company Drug

Jiangsu Hengrui Medicine’s SHR-1905 and SHR7280 Receive NMPA Clinical Trial Approvals

Fineline Cube Jun 1, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals from...

Posts pagination

1 … 570 571 572 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.